PTO/SB/21 (01-03) Approved for use through 04/30/2003. OMB 0851-0031 U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information poless it displays availed OMB control number. Application Number (09/866,536 TRANSMITTAL Filing Date 5/24/2001 **FORM** First Named Inventor Peter David Gluckman Art Unit (to be used for all correspondence after initial filing) 1639 Examiner Name Bennett M. Celsa Attorney Docket Number NRNZ-01002US3 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Alteched of Appeals and Interferences Appeal Communication to Group 1 Petition Amendment/Reply (Appeal Notice, Erief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Change of Correspondence Address Affidavits/declaration(s) Status Letter Other Enclosure(s) (please Terminal Disclaimer **Extension of Time Request** Identify below): Request for Refund Express Abandonment Request CD. Number of CD(s) Information Disolosure Statement Remarks Certified Copy of Priority OFFICIAL **FAX RECEIVED** Document(s) Response to Missing Parts/ MAR 1 4 2003 incomplete Application Response to Missing Parts under:37 CFR 1.52 or 1.53 **GROUP 1600** SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm D. Benjamin Borson Registration No.: 42,349 Fliesler Dubb Mever & Loveiov LLP <u>Individual</u> Signature Date 3/13/2003 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this currespondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patenta, Washington, DC 20231 on this date: 3/13/2003 Typed or printed <u>Benjamin Borson,</u> Reg. No. 42,349 3/13/2003 Signature Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the including case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, pall 1-800-PTO-9199 (1-800-788-9199) and select option 2.

	Attorney Docket No.:NRNZ-1002US3
Received 1	rom < 415 362 2928 > at 3/13/03 1:19:24 PM [Eastern Standard Time]



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s):

Peter D. Gluckman, et al.

SC/Serial No.: 09/866.536

Confirm. No.: 4791

Filed:

May 24, 2001

Title: METHODS TO IMPROVE NEURAL OUTCOME

Examiner:

Bennett M. Celsa

Customer No. 23910

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted by facsimile to the Commissioner for Patents, the United States Patent and Trademark Office Examining Group 1639 at Facsimile No. 703-872-9306 on March 13, 2003.

D. Benjamin Borson, Reg. No

Signature Date: March 13, 2003

RESPONSE TO OFFICE ACTION UNDER 37 C.F.R. § 1.111

Commissioner for Patents Washington, DC 20231

Sir:

This RESPONSE is in reply to the Office Action mailed February 25, 2003. The Examiner has issued an election of species requirement. The Examiner has indicated that there are six separate species identified in Claim 1 as a junior claim. They are a) GPE; b) a Prodrug of GPE; c) GPE analog; d) Prodrug of a GPE analog; e) GPE mimetic; and f) Prodrug of a GPE mimetic. The Applicants herein elect species a) drawn to GPE. All of the claims in this case read on GPE. This election is made without traverse. For the convenience of the Examiner all of the claims are reproduced below.

Amendments

Please amend the application as follows.

-1-

Attorney Docket No.: NRNZ-1002US3 DBB dbb/nrnz/1002us3.resp1.wpd

104.001:100101 03/13/03-10:02